CME Group’s institutional liquidity moat and $95 billion of daily margin efficiencies outweigh FMX concerns, supporting a $320.64 probability-weighted five-year target.
Overview
CME Group operates a systemically important, transaction-centric derivatives marketplace spanning interest rates, equity indexes, foreign exchange, energy, agriculture, and metals. Clearing and transaction fees generated $1.35 billion of Q2 2026 revenue, while recurring market-data revenue reached a record $238.1 million after 33 consecutive quarters of year-over-year growth. **The core investment case is CME’s liquidity and clearing moat:** 94% of volume comes from institutional participants, and CME Clearing produced more than $95 billion of daily margin efficiencies in Q2 2026, creating substantial switching costs. Q2 revenue was $1.7062 billion versus $1.6920 billion a year earlier; adjusted diluted EPS of $2.99 beat the $2.91 Zacks consensus and $2.95 broader Wall Street consensus. First-half 2026 volumes were 10% ahead of 2025, revenue was up 8%, and adjusted EPS rose 10%; July volumes were tracking 18% higher. Shares rose 5.78% to $251.11 after earnings, but remain below the 50-day and 200-day averages. The report views the stock as fairly valued with attractive long-term compounding potential, supported by Single Stock Futures, Treasury Link, and a probability-weighted five-year target of $320.64.